Literature DB >> 29150734

The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing's sarcoma cell line.

Christian Marx1, Lisa Marx-Blümel2,3, Nora Lindig2,3, René Thierbach4, Doerte Hoelzer4, Sabine Becker2,3, Susan Wittig2,3, Roland Lehmann5, Hortense Slevogt5, Thorsten Heinzel6, Zhao-Qi Wang1, James F Beck2, Jürgen Sonnemann7,8,9.   

Abstract

The sirtuin 1/2 inhibitor tenovin-1 activates p53 and may have potential in the management of cancer. Here, we investigated the responsiveness of Ewing's sarcoma cells to tenovin-1. We examined its effects in two Ewing's sarcoma cell lines with different p53 status, i.e. in p53 wild-type and p53 null cells. Effects were assessed by flow cytometric analyses of cell death, mitochondrial membrane depolarization and reactive oxygen species (ROS) generation, by caspase 3/7 activity measurement, by mRNA expression profiling and by immunoblotting. Tenovin-1 elicited caspase-mediated cell death in p53 wild-type cells, but caspase-independent cell death in p53 null cells. Remarkably, it induced a nonlinear concentration response in the latter: low concentrations of tenovin-1 were much more effective than were higher concentrations. Tenovin-1's effects in p53 null cells involved gene expression changes of Bcl-2 family members, mitochondrial membrane depolarization, nuclear translocation of apoptosis-inducing factor, ROS formation and DNA damage; all these effects followed a bell-shaped pattern. In conclusion, our results provide new insights into tenovin-1's mode of action by demonstrating that it can induce different pathways of cell death.

Entities:  

Keywords:  Apoptosis-inducing factor (AIF); Ewing’s sarcoma; Nonlinear response; Sirtuins; Tenovin-1; p53

Mesh:

Substances:

Year:  2017        PMID: 29150734     DOI: 10.1007/s10637-017-0541-1

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  33 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

Review 2.  Mitochondrial membrane permeabilization in cell death.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Catherine Brenner
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

3.  RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.

Authors:  Jürgen Sonnemann; Désirée Grauel; Lisa Blümel; Julia Hentschel; Christian Marx; Annelie Blumrich; Katharina Focke; Sabine Becker; Susan Wittig; Sandra Schinkel; Oliver H Krämer; James F Beck
Journal:  Eur J Cancer       Date:  2015-03-19       Impact factor: 9.162

4.  Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.

Authors:  Jürgen Sonnemann; Linn Dreyer; Maite Hartwig; Chithra D Palani; Le Thi Thu Hong; Ulrike Klier; Barbara Bröker; Uwe Völker; James F Beck
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-08       Impact factor: 4.553

Review 5.  Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.

Authors:  Nathalie Gaspar; Douglas S Hawkins; Uta Dirksen; Ian J Lewis; Stefano Ferrari; Marie-Cecile Le Deley; Heinrich Kovar; Robert Grimer; Jeremy Whelan; Line Claude; Olivier Delattre; Michael Paulussen; Piero Picci; Kirsten Sundby Hall; Hendrik van den Berg; Ruth Ladenstein; Jean Michon; Lars Hjorth; Ian Judson; Roberto Luksch; Mark L Bernstein; Perrine Marec-Bérard; Bernadette Brennan; Alan W Craft; Richard B Womer; Heribert Juergens; Odile Oberlin
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

6.  Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein.

Authors:  Fumihiko Nakatani; Kazuhiro Tanaka; Riku Sakimura; Yoshihiro Matsumoto; Tomoya Matsunobu; Xu Li; Masuo Hanada; Takamitsu Okada; Yukihide Iwamoto
Journal:  J Biol Chem       Date:  2003-01-30       Impact factor: 5.157

Review 7.  Sirtuins in Cancer: a Balancing Act between Genome Stability and Metabolism.

Authors:  Seung Min Jeong; Marcia C Haigis
Journal:  Mol Cells       Date:  2015-09-18       Impact factor: 5.034

8.  SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth.

Authors:  L Ma; W Maruwge; A Strambi; P D'Arcy; P Pellegrini; L Kis; A de Milito; S Lain; B Brodin
Journal:  Cell Death Dis       Date:  2014-10-23       Impact factor: 8.469

9.  Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Authors:  Sonia Lain; Jonathan J Hollick; Johanna Campbell; Oliver D Staples; Maureen Higgins; Mustapha Aoubala; Anna McCarthy; Virginia Appleyard; Karen E Murray; Lee Baker; Alastair Thompson; Joanne Mathers; Stephen J Holland; Michael J R Stark; Georgia Pass; Julie Woods; David P Lane; Nicholas J Westwood
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

10.  Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation.

Authors:  Sachiko Hirai; Shinji Endo; Rie Saito; Mitsuaki Hirose; Takunori Ueno; Hideo Suzuki; Kenji Yamato; Masato Abei; Ichinosuke Hyodo
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

View more
  4 in total

Review 1.  As a Modulator, Multitasking Roles of SIRT1 in Respiratory Diseases.

Authors:  Yunxin Zhou; Fan Zhang; Junying Ding
Journal:  Immune Netw       Date:  2022-06-20       Impact factor: 5.851

2.  The Fungal Metabolite Eurochevalierine, a Sequiterpene Alkaloid, Displays Anti-Cancer Properties through Selective Sirtuin 1/2 Inhibition.

Authors:  Michael Schnekenburger; Véronique Mathieu; Florence Lefranc; Jun Young Jang; Marco Masi; Anake Kijjoa; Antonio Evidente; Hyun-Jung Kim; Robert Kiss; Mario Dicato; Byung Woo Han; Marc Diederich
Journal:  Molecules       Date:  2018-02-05       Impact factor: 4.411

3.  Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology.

Authors:  Marcus J G W Ladds; Gergana Popova; Andrés Pastor-Fernández; Srinivasaraghavan Kannan; Ingeborg M M van Leeuwen; Maria Håkansson; Björn Walse; Fredrik Tholander; Ravi Bhatia; Chandra S Verma; David P Lane; Sonia Laín
Journal:  J Biol Chem       Date:  2020-09-08       Impact factor: 5.157

4.  Cooperative treatment effectiveness of ATR and HSP90 inhibition in Ewing's sarcoma cells.

Authors:  Jürgen Sonnemann; Zhao-Qi Wang; Christian Marx; Marc U Schaarschmidt; Joanna Kirkpatrick; Lisa Marx-Blümel; Melisa Halilovic; Martin Westermann; Doerte Hoelzer; Felix B Meyer; Yibo Geng; Katrin Buder; Hauke M Schadwinkel; Kanstantsin Siniuk; Sabine Becker; René Thierbach; James F Beck
Journal:  Cell Biosci       Date:  2021-03-20       Impact factor: 7.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.